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EFFECT OF INSULIN ON BRADYKININ-INDUCED  INTRACELLULAR CALCIUM MOBILIZATION IN  CULTURED HUMAN ENDOTHELIAL CELLS. Y. Takagawa, MT Hori, and ML Tuck. Veterans Administration GLHCS, Sepulveda, CA and UCLA School of Medicine, Los Angeles, CA
The acute vasodilatory effects of insulin are now generally established and it is also possible that insulin resistance reduces this vasodilatory effect. The precise mechanism(s) of insulin-induced vasorelaxation are only partially understood. One possible pathway of insulinmediated vascular effects may be nitric oxide synthase stimulation via elevation of intracellular calcium ([Ca2+] i) in endothelial cells. To further elucidate insulin's effect on this mechanism, we investigated the effect of insulin on bradykinin (BK) induced [Ca"]i responses in cultured human arterial vascular endothelial cells (HAVEC) using the calcium-indicating dye fura2. The effects of insulin (100 mu/ml) on basal and peak BK-induced [Ca*']i (10 PM), as well as on the sustained [Ca"]i response 10 minutes after BK addition were compared. Insulin treatment had no effect on basal calcium levels. Peak BK-induced intracellular calcium was elevated by insulin preincubation compared to vehicle control (152.9k16.7 vs. 144.7h22.2 nM, respectively). Moreover, 10 minutes after BK stimulation [Cal'], remained elevated in the insulin treated group (126.0+12.2 &I), while the control group returned more rapidly towards basal levels (108.9*17.2 nM, p ~0.05). We conclude that insulin may affect BK-induced vasodilatory responses by modulating calcium signaling pathways in HAVEC. Tumor necrosis factor-a (TNF) acts in an autocrine manner to inhibit *'Rb uptake ln the medullary thick ascending limb (mTAL). This effect, which is consistent with the observed natriuretic action of TNF, occurs via a prostanoid-dependent mechanism that requires induction of COX-2 gene transcription and protein expression, Pretreatment of mTAL cells with dexamethasone (DEX; 10 l&f) inhibited TNF-mediated COX-2 expression by approximately 95%.
Thus, we assessed the effects of adrenalectomy (AdrX) on renal COX-2 expression. COX-2 expression was evident in a subset of tubular epithelial cells located in the cortex and outer medulla. Staining of serial sections showed that COX-2-positive cells also contained Tamm-Horsfall glycoprotein, a highly selective marker for TAL cells.
These cells were located at a considerable distance from the corresponding macula densa, although they occasionally were close to glomeruli. Less than 2% of TAL cells were COX-2-positive in sham-operated rats, whereas more than 25% of TAL cells expressed COX-2 after AdrX. Treatment of AdrX rats with DEX (AdrX+DEX, 1 mg/kg) reduced the number of COX-2-positive cells to levels observed in sham-operated rats (l-2%).
Western blot analysis of cortical microsomes revealed a COX-2 protein band in AdrX rats but not in AdrX + DEX or sham-operated rats. Similarly, COX-2 mRNA accumulation was greatly increased by AdrX and was completely abolished by treatment with DEX. The increase in COX-2 mass observed after AdrX was associated with expression of active enzyme as demonstrated by a 3-fold increase in PGE, formation by cortical microsomes obtained from AdrX rats compared to sham-operated rats. We conclude that: 1) AdrX increases expression of enzymatically active COX-2 in the TAL, and 2) glucocorticoids act as endogenous inhibitors of COX-2 in The ability of the D,-like receptor to stimulate adenylyl cyclase (AC) and phospholipase C (PLC), inhibit sodium transport in the renal proximal tubule (RPT), and produce natriuresis is attenuated in several rat models of hypertension. Since the inhibitory effect of D,-like receptors on RPT sodium transport is also reduced in some patients with essential hypertension, we measured D,-like receptor coupling to AC in cultures of human RPT cells from nonnotensive (NT) and hypertensive (HT) subjects. Basal CAMP concentrations were the same in NT (n=7) and HT (n=S). However, the D,-like receptor agonist, fenoldopsm, increased CAMP production to a greater extent in NT (maximum response [Emax] = 67 f 1%) than in HT(Emax = 17 f 5 %). Dopamine also increased CAMP production to a greater extent in NT (32 f 3%) than in HT (14 i 3 %). The fenoldopam-mediated increase in CAMP production was blocked by SCH 23390 (a D,-like receptor antagonist) and by antisense D, oligonucleotides in both HT and NT, indicating action at the D, receptor. The stimulatory effects of forskolin and parathyroid hormone-related protein (PTHrP) of CAMP accumulation were not statistically different in NT and HT, indicating receptor specificity and an intact G-protein/AC pathway. The fenoldopam-stimulated PLC activity was not impaired in HT, and the primary sequence and expression ofthe D, receptor were the same in NT and HT. However, D, receptor serine phospholylation in the basal state was greater in HT (n=5) than in NT(n=4) and was not responsive to fenoldopam stimulation in HT. We conclude that uncoupling of the D, receptor in renal proximal tubules in both rats and humans may be due to ligand-independent phospholylation of the D, receptor in hypertension, Gene or genes involved in the phosphorylation of the D, receptor may be important in the pathogenesis of hypertension. Omapatrilat. a novel vasopeptidase inhibitor, is a single molecule that simultaneously inhibits neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). Inhibition of NEP protects vasodilator peptides (natriuretic peptides. bradykinin, adrenomedullin) from degradation and lowers blood pressure in low renin states. ACE inhibition attenuates the formation of angiotensin II and lowers blood pressure in normal/high renin states. The purpose of this study was to determine if omapatrilat produces dose-related antihypertensive effects in normal and low renin hypertensive rat models. Spontaneously hypertensive rats (SHR. normal renin) and deoxvcorticosterone acetate-salt hvoertensive rats IDOCA. low reninj were treated with oral omapairilat at 0, 10. 36. or 100 pmollkg once daily for 7 days. Baseline systolic blood pressure @BP) in SHR before each dose was 199~4,188f3,198iZ. and 204f4 mm Hg. respectively, and in DOCA rats was 218f8, 203*5,205*4. and 218f5 mm Hg. Results are summarized in the 
